Cartalax 20 mg: research material

Buy Cartalax 20 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.

Cartalax is a tripeptide research material associated with the AED reference sequence: alanine-glutamic acid-aspartic acid.

Choose the material and presentation

AED identifies three residues in a particular order. It differs from EDL, another short peptide used in the kidney-culture study below, and from a tissue-derived polypeptide complex containing multiple components.

The 20 mg label states the amount of material in this presentation. It does not specify a prepared solution concentration. For method matching, check the sequence and any stated chemical form rather than relying on a tissue-related product name.

What AED peptide studies measured

In kidney cultures from young and old rats, investigators compared AED and EDL with a calf-kidney polypeptide complex. The short peptides stimulated proliferation and reduced apoptosis-associated responses, but their effects were less pronounced than those of the complex. The preparations were separate experimental materials.

A second study in human skin fibroblasts examined AED during replicative aging in culture. AED increased synthesis of sirtuin 1, sirtuin 6 and type I collagen under the tested conditions.

These findings describe laboratory endpoints in different models. They do not demonstrate cartilage repair or a clinical anti-aging effect, and a result for a complex preparation should not be assigned to AED alone.

Original study

Product records and batch reports

The product documentation section provides available batch reports and product files. Check the product identity and lot alongside the analytical method and reported results. Purity, measured content and a biological response are different measurements.

Use lot-specific records for the supplied material. Storage temperatures, shelf life or a purity percentage from another supplier’s page should not be transferred to this product without supporting documentation.